a public good project by the
Synthesis
Company
of California

© 2026

Dong‐Wan Kim | doi.page

0 works0 citations0 h-index

Dong‐Wan Kim

Seoul National University(KR)Korea University(KR)New Generation University College(ET)Seoul National University Hospital(KR)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Gastric Cancer Management and Outcomes, HER2/EGFR in Cancer Research, Colorectal Cancer Treatments and Studies

Most-Cited Works

→ Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial(2015)6,477 cited
→ Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer(2017)2,413 cited
→ Virus-Enabled Synthesis and Assembly of Nanowires for Lithium Ion Battery Electrodes(2006)1,848 cited
→ Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study(2012)1,275 cited
→ First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer(2020)1,028 cited
→ Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib(2005)775 cited

→ Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity(2016)707 cited

→ Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study(2021)605 cited

→ Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial(2017)579 cited

→ Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study(2018)570 cited